It was found that compared with regorafenib treatment alone, the phosphorylation of VEGFR2 and its downstream signaling pathway FAK in HCC cells was decreased after treatment with 50 mV/mm electric fields and regorafenib (Figure 1H). The gene discussed is PTK2; the disease is hepatocellular carcinoma.